Eli Lilly and Company
Douglas Kiehl is a Research Advisor at Eli Lilly and Company and leads the Advanced Structural Characterization, Trace Analysis, Extractables/Leachables and Elemental Impurities team. With over 38 years' experience with application of advanced mass spectrometry in characterization of diverse chemical entities, 26 years in the Pharmaceutical Industry. He is a member of the USP Packaging and Distribution Expert Committee, Vice Chair for the PQRI (Product Quality Research Institute) Development Technical Committee, PhRMA Topic Lead for the ICH Q3E Expert Working Group, the USP Expert Panel on Biocompatibility of Materials Used in Packaging Systems, Medical Devices and Implants, the USP Expert Panel on Elastomeric Closure for Injections, Board of Directors for the ELSIE Consortium, Chair for the SPIE Defense and Commercial Sensing Conference and member of the AAPS Impurities Steering Committee. His research interests include the development of advanced mass spectrometry-based mapping and visualization techniques to enable the rapid and comprehensive characterization of highly complex mixtures of structurally and compositionally diverse chemical entities. He also leads multidisciplinary efforts to advance ultrarapid threat detection and development, manufacture and deployment of pharmaceutical countermeasures for catastrophic (e.g. pandemic, environmental disaster, etc.) unanticipated medical needs and point-of-use patient therapies.